@natureportfolio.nature.com
A phase 2 clinical trial has demonstrated that bimagrumab, when combined with semaglutide, resulted in significant weight loss for trial participants while maintaining lean muscle mass – suggesting a promising approach for obesity treatment. The findings are published in Nature Medicine. 🧪
